Top Cel­gene ex­ec pins the blame for ozan­i­mod fi­as­co on the Re­cep­tos team — ac­quired 3 years ago

Cel­gene’s top ex­ecs have been reel­ing for months, stag­gered by the FDA’s de­ci­sion to kick back their ap­pli­ca­tion on ozan­i­mod, the big drug in the late-stage pipeline that is bad­ly need­ed as the com­pa­ny looks to build new rev­enue and lessen its de­pen­dence on Revlim­id price hikes. And now one of the lead­ers in­volved in the em­bar­rass­ing refuse-to-file set­back with ozan­i­mod isn’t just agree­ing that their ap­pli­ca­tion was in­ad­e­quate, he’s point­ing fin­gers di­rect­ly at the team they brought in when they ac­quired the drug with their $7.2 bil­lion Re­cep­tos buy­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER